Email ID
Password
Sign me in automatically next time

Lessons in Lifecycle Management
6 May 2011

 


Fred HassanFred Hassan: Getting traction with lifecycle management

Insights from industry veteran Fred Hassan on the crucial strategic, risk diversification issue of lifecycle management. Mr Hassan provides his personal perspectives on why superior LCM expertise matters and how to instil it in your company. He discusses LCM’s increasing importance in reaching R&D cost-of-capital thresholds, untapped strategic opportunities ahead, and the leadership necessary to overcome cultural and operational roadblocks in LCM.

Read more:

Fred Hassan: Getting traction with lifecycle management
LCM: Defining successors, flankers and toppers


Shine a light on any challenged pharmaceutical product or therapeutic area and you'll likely gain some insight into companies' past, present and future strategies in the increasingly critical area of lifecycle management. Very often, the more difficult the challenge, the more interesting the approaches taken to tackle it.

Lessons in Lifecycle Management is our new quick-reference collection of 50 drug case studies from the recent history of some of the world's leading pharma companies. This is not an encyclopaedia of every lifecycle strategy, but an attempt to generate timely intelligence on the planning and nurturing of product lifecycles.

These lessons take an analytical viewpoint: some orthodox, others less so. We hope they are of use in your deliberations, conversations or machinations to deliver the most value to your own customers, companies and shareholders.... Read more

Quick links

Lipitor lifecycle case study



All 50 lifecycle case studies | Lipitor in detail
Interactive: Browse lessons



Animation: Sneha Sowdi


Get the case studies

Chris Bowe50 lessons in lifecycle management
Christopher Bowe

Here’s a challenge for senior pharma executives everywhere – regardless of business function. Take a quick survey in your office. Ask one very simple question: “What is lifecycle management?” How often did you hear it described as “line extensions?” Otherwise, was there any broad agreement on what else constitutes the ideal pursuit of maximum value in a product's life in the pharmaceutical industry?

If the answers or your findings do not satisfy you, it is not surprising. And yet this is a subject that is very much at the heart of the real core business of pharma. These days, molecules are hard-won no matter how they are acquired. Read more

Interactive: Company index


Animation: Sneha Sowdi

Lifecycle management in practice

Vimovo - turn back the clock to 2005
Christopher Bowe

The best of lifecycle management lessons typically have one, if not both, of these things at their nucleus: creativity and timing.
Gloves off in the MS market - a lifecycle management exercise to behold
Christopher Bowe

Disruption is always as messy as it sounds, and so it is in the innovative market for multiple sclerosis drugs.
Lilly sees stellar growth in Japan on raft of new approvals
Ian Haydock

Lilly may be facing a series of challenges to its overall business, but Japan is proving to be something of a powerhouse for the US firm.
Eisai links with Teikoku for transdermal Aricept in Japan
Ian Haydock

Eisai has exercised an option to develop in Japan a transdermal formulation of its top-selling Alzheimer's disease therapy Aricept (donepezil) under an alliance with Teikoku Seiyaku.
Ziopharm's darinaparsin set for Asian development under Solasia deal
Ian Haydock

The Japanese venture Solasia Pharma has expanded its pipeline with the acquisition of exclusive development and commercialisation rights in 13 Asian markets to Ziopharm Oncology's anticancer Zinapar (darinaparsin).
Failed Bydureon study leaves Wall Street asking 'What the Gila?'
Donna Young

Amylin and Lilly may have overplayed their hand when they put their experimental once-weekly formulation of exenatide, a synthetic drug derived from the saliva of the Gila monster lizard, up against Novo Nordisk's FDA-approved Victoza (liraglutide) in an attempt to show which drug was best in reducing A1c in Type 2 diabetes.

Editorial team

Scrip Intelligence
Editor, Scrip Analysis: Pete Chan
Editorial Coordinator: Rebecca Debens

Multimedia and Graphic Design
Flash Animator, Video editor: Sneha Sowdi
Data visualisation, PDF design: Paul Wilkinson
Videographer: Dale Perkins
Web Editor: Salina Christmas
US Healthcare Analyst
Christopher Bowe


EVENTS
17 September 2013
Radisson BLU, Berlin, Germany
JOB OF THE WEEK Our latest jobs
© 2013 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36

In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer.

By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way Scrip Intelligence uses cookies please go to our Cookie Policy page.